The Food and Drug Administration said Wednesday that it would review of the safety of the widely used anemia drugs sold by Amgen and Johnson & Johnson after another clinical trial suggested that high doses of one of the drugs might cause strokes.
58902
FDA to review safety of anemia drugs from Amgen and Johnson & Johnson
72746
Drug originally intended to lower
167980
Celgene presents data for three Phase II studies of Revlimid
6140
Inadequate nutrition linked to greater risk of anemia in postmenopausal women
61304
Health officials shoot down approval for weight loss drug
16901
J&J wins approval for expanded use of HIV drug
39357
Dietary supplements may have an adverse effect on chemotherapy treatments
140534
Bill would expand access to clinical trials
168915
Weight loss pill could cause liver damage
29470
Health regulators warn about tanning drug
62713
FDA warns Rockstar:
157348
Abbott Laboratories issues recall for Similac infant formula.
17009
Doctors may be overprescribing drugs for heart conditions
133227
Aspirin to prevent atherosclerosis
37199
Bionovo (bnvi) to present positive results from phase 2 trial of Menerba
21654
FDA approves Bydureon
61180
FDA amends animal drug regulations